Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial

Eugene Han; Ji Hye Huh; Eun Y. Lee; Ji C. Bae; Sung W. Chun; Sung H. Yu; Soo H. Kwak; Kyong S. Park; Byung Wan Lee

doi:10.1111/dom.14623

Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial

Eugene Han
, Ji Hye Huh
, Eun Y. Lee
, Ji C. Bae
, Sung W. Chun
, Sung H. Yu
, Soo H. Kwak
, Kyong S. Park
, Byung Wan Lee

Department of Internal Medicine

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	752-756
Number of pages	5
Journal	Diabetes, Obesity and Metabolism
Volume	24
Issue number	4
DOIs	https://doi.org/10.1111/dom.14623
State	Published - Apr 2022

Bibliographical note

Funding Information:
The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI‐PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong‐A ST Co. Ltd.

Funding Information:
The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI-PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong-A ST Co. Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

dipeptidyl peptidase-4 inhibitor
evogliptin
magnetic resonance imaging-derived proton density fat fraction
non-alcoholic fatty liver disease
pioglitazone
type 2 diabetes

Access to Document

10.1111/dom.14623

Cite this

@article{e66d0b5394bc4b509071c63599837ff6,

title = "Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial",

keywords = "dipeptidyl peptidase-4 inhibitor, evogliptin, magnetic resonance imaging-derived proton density fat fraction, non-alcoholic fatty liver disease, pioglitazone, type 2 diabetes",

author = "Eugene Han and Huh, \{Ji Hye\} and Lee, \{Eun Y.\} and Bae, \{Ji C.\} and Chun, \{Sung W.\} and Yu, \{Sung H.\} and Kwak, \{Soo H.\} and Park, \{Kyong S.\} and Lee, \{Byung Wan\}",

note = "Funding Information: The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI‐PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong‐A ST Co. Ltd. Funding Information: The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI-PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong-A ST Co. Ltd.",

year = "2022",

month = apr,

doi = "10.1111/dom.14623",

language = "English",

volume = "24",

pages = "752--756",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease

T2 - A multicentre, double-blind, randomized, comparative trial

AU - Han, Eugene

AU - Huh, Ji Hye

AU - Lee, Eun Y.

AU - Bae, Ji C.

AU - Chun, Sung W.

AU - Yu, Sung H.

AU - Kwak, Soo H.

AU - Park, Kyong S.

AU - Lee, Byung Wan

N1 - Funding Information: The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI‐PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong‐A ST Co. Ltd. Funding Information: The authors wish to acknowledge Professor Jin Young Choi, Department of Radiology, Yonsei University College of Medicine, for help with analysing MRI-PDFF images, and Professor Seung Up Kim, Division of Hepatology, Department of Internal Medicine, Yonsei University College of Medicine, for help with interpreting the significance of the results of this study. This study was supported by Dong-A ST Co. Ltd.

PY - 2022/4

Y1 - 2022/4

KW - dipeptidyl peptidase-4 inhibitor

KW - evogliptin

KW - magnetic resonance imaging-derived proton density fat fraction

KW - non-alcoholic fatty liver disease

KW - pioglitazone

KW - type 2 diabetes

UR - https://www.scopus.com/pages/publications/85121698174

U2 - 10.1111/dom.14623

DO - 10.1111/dom.14623

M3 - Letter

C2 - 34918436

AN - SCOPUS:85121698174

SN - 1462-8902

VL - 24

SP - 752

EP - 756

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 4

ER -

Efficacy and safety of evogliptin in patients with type 2 diabetes and non-alcoholic fatty liver disease: A multicentre, double-blind, randomized, comparative trial

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Cite this